Ultra-thinly traded Medigene AG (OTCPK:MDGEF +35%) is up, albeit on a miniscule 1,400 shares, on the heels of topline data from a Phase 1/2 clinical trial evaluating its autologous dendritic cell vaccine in 20 acute myeloid leukemia (AML) patients.
At month 24, the rate of overall survival (OS) was 80% (n=16/20) and the rate of progression-free survival (PFS) was 55% (n=11/20).
Detailed results will be submitted for presentation at future medical conferences.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.